Moreover, a recent first-in-human trial confirmed that adoptive transfer of T cells retrovirally transduced with a tumor-reactive TCR and edited at the TRAC, TRBC and PDCD1 loci by CRISPR/Cas9 was safe and feasible (28). This evidence concerns the gene PDCD1 and neoplasm.